德銀相隔七年再被納入泛歐STOXX 50指數 諾基亞及Stellantis被剔出
泛歐STOXX 50指數的指數公司ISS Stoxx宣布,把德銀、西門子能源及生物科技公司Argenx納入指數,剔出諾基亞,車廠Stellantis及法國干邑商Pernod Ricard,變更於本月22日開市時生效。
德銀事隔七年再被納入該指數,該股過去一年累升逾倍。西門子能源股價自去年9月以來升逾兩倍,受全球電子需求急升推動。Argenx在癌症及自體免疫疾病藥物的銷售及臨床數據正面,過去一年累升三成。諾基亞、Stellantis及Pernod Ricard則受美國關稅影響,過去一年分別累跌7%、46%及24%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.